The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.
Ironwood Pharmaceuticals has announced the initiation of a New Drug Application (NDA) submission for apraglutide for the treatment of short bowel syndrome (SBS) who are dependent on parenteral support.1
Mike Shetzline, MD, PhD
Credit: Ironwood Pharmaceuticals
According to a January 29, 2025, release, in addition to initiating a rolling NDA submission, the company plans to announce new data from its open-label extension study, STARS Extend, demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time. Of note, this long-term extension data will be included in the NDA, along with efficacy and tolerability data from STARS.1
“With these new data, we are even more encouraged about apraglutide’s potential to help SBS patients who are dependent on parenteral support,” said Mike Shetzline, MD, PhD, chief medical officer, senior vice president, and head of research and drug development at Ironwood.1
Data from the multicenter, double-blind, randomized, placebo-controlled phase 3 STARS trial were presented during a late-breaking session at Digestive Disease Week (DDW) 2024 in Washington, DC, and showed significantly more patients treated with apraglutide gained additional days off from parenteral support per week and were clinical responders or clinical high responders, building upon previous positive topline data announced earlier in 2024. It was conducted in 18 countries with enrollment from 68 study sites and is the largest global SBS-IF clinical trial to date, involving a total of 164 patients who were randomly assigned in a 2:1 ratio to receive once weekly apraglutide or placebo, stratified by remnant bowel anatomy, and evaluated over 24- and 48-week periods.2
Ironwood previously reported the STARS trial met its primary endpoint of relative change from baseline in actual weekly parenteral support volume at week 24 compared to placebo (-25.5% vs -12.5%; P = .001), driven by both stoma and colon-in-continuity subpopulations. Additionally, treatment effect with relative parenteral support volume reduction was observed from week 8 onward (-8% vs -1.6%; P = .002).1
Data presented at DDW showed significantly more apraglutide patients gained additional days off from parenteral support per week at week 24 versus placebo (≥ 2 days, 24.5% vs 11.3%; P = .021 and ≥ 3 days, 11.8% vs 1.9%; P = .006). Additionally, significantly more patients treated with apraglutide were clinical responders and clinical high responders, defined as ≥20% and ≥40% parenteral support volume reduction, respectively, at both weeks 20 and 24 versus placebo.1
Of note, in order to position the company for long-term growth with apraglutide, Ironwood announced plans to reduce its workforce by approximately 50%.1
“Ironwood’s long track record of success stems from our ability to be nimble as an organization by focusing on both significant medical needs and financial performance. While LINZESS continues to grow prescription demand, given the impact of ongoing pricing pressures, we are taking steps to reduce Ironwood costs that are predominantly associated with the brand. By doing so, we believe we can continue to generate profits and cash flows and support the successful development of apraglutide,” said Tom McCourt, chief executive officer of Ironwood, who added that the company’s apraglutide launch planning is “well underway” with “strong commercial capabilities to support the future success of apraglutide, if approved.”
References
Clarifying the Role of EEN Diet as Ulcerative Colitis Therapy
March 12th 2025There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to a systematic review.
Read More
Addressing Disparities in IBD Care to Reduce Costs and Improve Access
March 11th 2025Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments, increasing biosimilar adoption, and implementing policies that reduce financial disparities and improve long-term patient outcomes.
Read More
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
March 10th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.
Read More
Crohn Disease Subtype, Ocular Manifestation Among Risk Factors for EIMs in IBD
February 24th 2025Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the highest risks among those with Crohn disease, ocular manifestations, or right-sided colonic involvement.
Read More
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Originator in IBD
February 20th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Read More